ClinicalTrials.gg
RecruitingNCT07027072Updated Jun 22, 2026

Study to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease

A Phase 2 interventional study of KDS2010 and Placebo in Mild Cognitive Impairment (MCI), Mild Dementia and Alzheimer's Disease, sponsored by NeuroBiogen Co., Ltd. Recruiting at 8 sites in South Korea. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by NeuroBiogen Co., Ltd · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 74 studies in Cognitive Dysfunction with a site in Korea, Republic of — 17 open to participants now, 24 under way, 5 of them phase 3. Cognitive Dysfunction · Korea, Republic of.

Planned enrollment
24th of 57
114 · median 94
Started
2025
with 12 others
Phase 2
4 of 74
2 open now
Primary completion
2027-06
later than 16 of 23 live
Registered
62nd of 74
by date

Among the 74 studies in Cognitive Dysfunction with a site in Korea, Republic of, this one is the 24th largest by planned enrollment of the 57 interventional ones that give a count, is one of 13 that started in 2025, is one of 4 in phase 2, reaches primary completion later than 16 of the 23 other live ones, and was the 62nd registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

17 of the 74 studies in Cognitive Dysfunction with a site in Korea, Republic of are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies in Cognitive Dysfunction with a site in Korea, Republic of, or all of them as a file.
02

Study summary

A randomized, double-blind, placebo-controlled, dose-finding Phase 2a clinical trial will be conducted to evaluate the efficacy and safety of KDS2010 in patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease (AD) and mild dementia due to Alzheimer's disease.

Based on preliminary efficacy observed in the Phase 1 clinical trial, a clinical trial will be conducted in Korea. Eligible patients diagnosed with MCI or mild Alzheimer's disease will be stratified by disease stage (MCI/mild AD) prior to randomization. Subjects will be randomly assigned in a 1:1:1 ratio to either Treatment Group 1, Treatment Group 2, or the Control Group. The investigational product will be administered orally once daily for a duration of 24 weeks. Approximately 114 subjects will be enrolled, including an estimated 20% dropout rate, with 38 subjects assigned to each group (Treatment Group 1, Treatment Group 2, and Control Group).

The objectives of the study are as follows:

  1. Efficacy Objectives: Efficacy will be evaluated through changes in cognitive function, self-management, and daily living activities before and after administration of KDS2010. Biomarker analysis in plasma and in cerebrospinal fluid (CSF; optional) will also be conducted to explore treatment efficacy.
  2. Safety Objectives: The safety and tolerability will be evaluated after administration of KDS2010.
  3. Exploratory Objectives: The efficacy of Treatment Groups 1 and 2 compared to the Control group will be explored through cognitive endpoints (the Clinical Dementia Rating-Sum of Boxes (CDR-SB), the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13), and the Mini-Mental State Examination (MMSE)), stratified by demographic information, tauopathy, and ApoE4 genes.

Based on nonclinical and Phase 1 clinical data, KDS2010 will be administered orally once daily at two dose levels: 60 mg and 120 mg.

Read the detailed description

This Phase 2a, randomized, double-blind, placebo-controlled, dose-finding clinical trial is designed to evaluate the efficacy, safety, and pharmacokinetics of KDS2010, a novel investigational product, reversible monoamine oxidase-B (MAO-B) inhibitor, in patients with Alzheimer's Disease (AD) with Mild Cognitive Impairment (MCI) and Mild Dementia due to Alzheimer's Disease. The clinical trial is conducted at selected sites in Korea.

A total of 114 subjects are planned for the study, with 38 subjects in each of the three groups: two treatment groups (receiving different doses of KDS2010) and a placebo control group. Subjects will be randomized in a 1:1:1 ratio, and the study is designed to allow for a 20% dropout rate. Inclusion criteria require that participants be aged between 50 and 85 years, diagnosed with MCI or mild AD, and amyloid-positive as confirmed by PET scans. Eligible participants must also demonstrate cognitive impairment as indicated by a CDR score between 0.5 and 1.0 and an MMSE score between 21 and 30.

Key exclusion criteria include individuals with cognitive impairment caused by conditions other than AD, those with a history of serious medical conditions such as cardiovascular disease or cancer, and individuals who have used AD-modifying agents or CNS-active drugs within 12 weeks prior to screening.

The primary efficacy endpoint is the change in cognitive function, assessed through the Clinical Dementia Rating-Sum of Boxes (CDR-SB), Mini-Mental State Examination (MMSE), and Alzheimer's Disease Assessment Scale-Cognitive 13 (ADAS-Cog13) scores. Secondary efficacy endpoints include changes in daily living activities (measured by the Activities of Daily Living Scale and the Alzheimer's Disease IADL Questionnaire), as well as biomarkers such as tauopathy and Apo-E4. Exploratory endpoints will assess cognitive decline and specific changes in brain imaging (e.g., PET scans) and cerebrospinal fluid biomarkers.

Safety will be evaluated through monitoring adverse events (AEs), vital signs, laboratory tests, ECGs, and psychological assessments, including the Columbia-Suicide Severity Rating Scale (C-SSRS). Pharmacokinetic parameters (AUCtau, Cmax,ss, Cmin,ss, Cav,ss, Tmax,ss, T1/2, and PTF, etc.) will be measured to assess systemic exposure to KDS2010.

Subjects must be aged between 50 and 85 years, diagnosed with MCI or mild AD, and amyloid-positive based on PET scan results. Inclusion criteria also require cognitive impairment as indicated by a CDR score between 0.5 and 1.0 and an MMSE score between 21 and 30. Major exclusion criteria include conditions other than AD that cause cognitive impairment, uncontrolled systemic diseases, and recent use of AD-modifying agents.

The primary aim of the study is to determine the potential of KDS2010 to slow cognitive decline in individuals with early-stage Alzheimer's disease, with secondary and exploratory objectives focused on safety, quality of life, and understanding the drug's pharmacokinetic profile. This study aims to provide important insights into the potential therapeutic benefits of KDS2010 in treating Alzheimer's disease at the early stages of cognitive decline.

The total duration of the study is expected to be approximately 30 months from IRB/IEC approval, with individual subject participation lasting up to 9 months. This trial aims to evaluate the safety, efficacy, and pharmacokinetics of KDS2010 as a potential treatment for early stages of Alzheimer's disease, with the goal of advancing the development of KDS2010 in the treatment of AD.

03

Conditions studied

  • Mild Cognitive Impairment (MCI)
  • Mild Dementia
  • Alzheimer's Disease

Keywords

  • Mild Cognitive Impairment
  • Mild Dementia
  • KDS2010
  • MAO-B inhibitor
  • Alzheimer's Disease
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female adults aged ≥50 and ≤85 years at the time of written consent
  • Patients with MCI or mild AD confirmed at screening according to the 2024 diagnostic criteria (APPENDIX 1) of the National Institute on Aging-Alzheimer's Association (NIA-AA)
  • Subjects whose total CDR score (CDR-GS) is 0.5 to 1.0 at screening (however, CDR memory score is ≥0.5)
  • Subjects with a (MMSE) score of 21 to 30 at screening
  • Subjects who test positive for amyloid on Positron Emission Tomography (PET) during screening
  • Subjects who have a caregiver capable of providing accurate information about the subject's cognitive and functional abilities and appropriate for the planned assessments in the study, as judged by the investigator
  • Subjects (or their legal representatives) who have voluntarily agreed to participate in this study and have given written consent

Exclusion criteria

Exclusion Criteria:

  • Cognitive impairment or dementia due to causes other than Alzheimer's disease

    • Vascular dementia, central nervous system infections (e.g., , syphilis, etc.), head trauma, Creutzfeldt-Jakob disease, Pick's disease, Huntington's disease, Parkinson's disease, subdural hematoma, normal pressure hydrocephalus, brain tumor, thyroid disorders, parathyroid disorders, Vitamin B12 deficiency, folic acid deficiency, other metabolic and nutritional deficiencies, etc.
    • Alcohol or drug abuse, dependence
  • Subjects with cognitive impairment due to hypothyroidism, nutritional deficiencies, Vitamin B12 or folic acid deficiency as assessed during screening
  • Subjects confirmed during screening to have had the following medical history:

    • Malignant tumors within five years prior to screening except for basal cell carcinoma, cutaneous squamous cell carcinoma, thyroid cancer, or carcinoma in situ that has not recurred in over three years and is considered successfully treated by the investigator
    • History of alcohol or drug abuse within two years prior to screening
    • Loss of consciousness of unknown cause, or seizure within the past 52 weeks before screening
    • Unstable and cardiovascular diseases despite appropriate treatment (acute coronary syndrome (ACS), tachycardia, clinically significant arrhythmias, cardiomyopathy, angina of at least CSS III, heart failure of II-IV, or clinically significant valvular heart disease) within 24 weeks before baseline
    • Severe or active infectious diseases requiring antibiotics or antivirals within four weeks before baseline
    • A history of stroke involving a major vascular area, (TIA), epilepsy, or severe head trauma with loss of consciousness
    • or allergy to any components of the product
  • Subjects confirmed during screening to have had the following accompanying disease:

    • Clinically significant neurological diseases or serious pathological findings affecting cognitive function as confirmed by brain imaging studies within 52 weeks prior to screening, including multiple sclerosis, normal pressure hydrocephalus, brain tumor (however, exceptions are allowed for lesions diagnosed as benign and with a maximum diameter of less than 1 cm), spinal cord infarction, major hemorrhage (defined as having a diameter > 1 cm in MRI) or subdural hemorrhage, cerebral vascular malformation, communicating hydrocephalus, inflammatory demyelinating diseases, etc.
    • Uncontrolled hypertension despite appropriate treatment at screening or baseline (SBP ≥160 mmHg or DBP ≥100 mmHg)
    • Dizziness or fainting when standing due to orthostatic hypotension that may affect the evaluation according to the judgment of the investigator
    • Uncontrolled diabetes ( > 9%) during screening, despite appropriate treatment
    • Bleeding disorders ( \<50,000/mm³) during screening, despite appropriate treatment
    • Patients with severe hepatic impairment ( class C) at screening
    • Following laboratory test values at screening:

      • or ALT > 2.5 x
      • total > 1.5 x ULN (however, in case of Gilbert syndrome, > 3.0 mg/dL)
      • eGFR \< 30 mL/min/1.73 m²
    • interval >450 msecs for male or 470 msecs for female(12-lead ) during screening
    • Gastrointestinal diseases that may affect oral administration or absorption (celiac disease, Crohn's disease, intestinal resection, etc.)
    • Gastrointestinal diseases, including gastric and duodenal ulcers, that may affect the safety evaluation according to the judgment of the investigator
    • Psychiatric diagnosis or symptoms that may interfere with the study (uncontrolled major depression, uncontrolled schizophrenia, uncontrolled bipolar affective disorder, etc.), as assessed by the investigator
    • Positive responses to items 4 or 5 on the Columbia University Suicide Severity Rating Scale (C-SSRS) during screening
    • Other conditions deemed by the investigator to potentially affect the outcome of the study
  • Subjects who have undergone or require treatment with the following:

    • AD disease-modifying agents (aducanumab, lecanemab, donanemab, gantenerumab, solanezumab, blarcamesine, simufilam, tricaprilin, valiltramiprosate, etc.) within 12 weeks before screening
    • Medications that may improve cognitive abilities or affect AD treatment (AChEIs, donepezil, galantamine, rivastigmine, tacrine, memantine, etc.) within 12 weeks before screening, except if the subject has been on a stable dose for at least 12 weeks before baseline and maintains the same composition/dosage/method of administration during the study period
    • CNS-active drugs or those affecting cognitive function antidepressants other than serotonergic drugs [e.g., bupropion], sedatives [e.g., carbamazepine], dopamine antagonists [e.g., antipsychotics, metoclopramide], amfepramone, mazindol) within 12 weeks before screening
    • Central anticholinergics and sedating H1-antihistamines within 12 weeks before screening.

However, exceptions are allowed for one-time use of the drugs, such as second-generation H1 antihistamines (e.g., cetirizine, levocetirizine, etc.) or peripheral anticholinergics with no central action (e.g., trospium for treating overactive bladder). But the use is prohibited for at least 3 days from the date of cognitive function evaluation.

  • Other investigational products or clinical trial devices within four weeks before baseline or five times the half-life of the drug (whichever is longer, and patients can be enrolled after wash-out)
  • Monoamine oxidase inhibitors (MAOIs) and linezolid within two weeks before baseline or five times the half-life of the drug (whichever is longer, and patients can be enrolled after wash-out)
  • Opioids (pethidine, tramadol, tapentadol, etc.) within two weeks before baseline or five times the half-life of the drug (whichever is longer, and patients can be enrolled after wash-out)
  • Cyclobenzaprine and St. John's wort within two weeks before baseline or five times the half-life of the drug (whichever is longer, and patients can be enrolled after wash-out)
  • The following serotonergic drugs within two weeks before baseline or five times the half-life of the drug (whichever is longer, and patients can be enrolled after wash-out),

    • selective serotonin (5HT1) agonists
    • lithium
    • lamotrigine
    • ritonavir
    • dapoxetine
    • Selective serotonin reuptake inhibitors (SSRIs)
    • dapoxetine
    • Serotonin-norepinephrine reuptake inhibitors (SNRIs)
    • Tricyclic or tetracyclic antidepressants
    • triazolopyridine antidepressant However, amitriptyline ≤ 50 mg/day, trazodone ≤ 100 mg/day, citalopram ≤ 20 mg/day, and sertraline ≤ 100 mg/day are allowed without washout.
  • Use of sympathomimetics (ephedrine, methylphenidate, amphetamine, methamphetamine, lisdexamfetamine, etc.) during the screening period
  • Use of Dextromethorphan during the screening period
  • Use of strong inducer, CYP3A4 strong inhibitor, CYP2D6 strong inducer, and CYP2D6 strong inhibitor during the screening period

    • Inability to undergo MRI or PET scans
    • Pregnant or breastfeeding women
    • Fertile women or men who are unwilling to use effective * from the date of written consent until 12 weeks after the last administration of the investigational product

      *Effective contraception is defined as follows, and at least one method should be used:

      • Hormonal contraception (oral, injectable, implantable, etc.)
      • Intrauterine device (IUD) or system (IUS)
      • Sterilization or surgical procedures (vasectomy, bilateral tubal ligation/surgery, hysterectomy)
      • Dual contraception methods: Simultaneous use of barrier methods (male condoms) with the methods listed above
      • Absolute abstinence: Total abstinence from sexual intercourse is recognized if the investigator deems the subject's age, occupation, lifestyle, or sexual orientation assures contraception. However, periodic abstinence (calendar method, mucus method, and symptothermal method), withdrawal, and coitus interruptus are not recognized as effective contraception methods.
    • Other conditions deemed by the investigator to be unsuitable for participation in the study
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
114 participants (estimated)

Study arms

  • Placebo comparator
    Control Group_Placebo

    A placebo will be administered orally once daily as two tablets per day for 24 weeks. This group will match the investigational drug in appearance but contain no active ingredients to maintain blinding.

    Drug: Placebo

  • Experimental
    Treatment Group 1_KDS2010 60 mg

    KDS2010 60 mg will be administered orally once daily as two tablets per day (one 60 mg KDS2010 tablet and one placebo tablet, 60 mg total) for 24 weeks. This group will receive the active investigational drug to evaluate its safety and efficacy.

    Drug: KDS2010

  • Experimental
    Treatment Group 2_KDS2010 120 mg

    KDS2010 60 mg will be administered orally once daily as two tablets per day (two 60 mg KDS2010 tablets, 120 mg total) for 24 weeks. This group will receive the higher dose of the investigational drug to evaluate its safety and efficacy.

    Drug: KDS2010

Interventions

  • DrugKDS2010

    KDS2010 will be administered orally once daily, two tablets per day, for 24 weeks. Dosage will be either 60 mg or 120 mg depending on the assigned group.

  • DrugPlacebo

    Placebo matching the investigational product in appearance but containing no active ingredient, administered orally once daily, two tablets per day, for 24 weeks.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) score

    Clinical Dementia Rating (CDR) is a tool developed to assess the clinical stages of Alzheimer's disease. CDR 0 indicates "no dementia," CDR 0.5 "questionable," CDR 1 "mild," CDR 2 "moderate," and CDR 3 "severe" dementia. The range for CDR-SB is 0 to 18 points, where higher scores indicate more severe dementia.

    Time frame: Screening (-8 Week~), Week 4, Week 8, Week 12, Week 24, Week 26

  2. Time to ≥0.5-point increase in CDR-SB

    Time from randomization to the first occurrence of ≥0.5-point increase in CDR-SB score.

    Time frame: Up to Week 26

  3. Change from Baseline in Mini-Mental State Examination (MMSE) score

    The MMSE is a cognitive function and disease severity assessment composed of 30 items. Each is graded on a 2-point scale where 1 point is awarded for correct performance and 0 points if not performed correctly. Lower total scores on the MMSE indicate cognitive impairment.

    Time frame: Screening (-8 Week~), Week 12, Week 24, Week 26

  4. Change from Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13) score

    ADAS-Cog13 is a comprehensive tool for the early diagnosis of dementia and the sensitive assessment of disease progression stages. The assessment includes 9 "neuropsychological tests" and 4 "clinical assessments of cognitive damage", totaling 13 items. The higher the total score of the ADAS-Cog, the more it indicates cognitive dysfunction.

    Time frame: Screening (-8 Week~), Week 12, Week 24, Week 26

  5. Change from Baseline in Amsterdam Instrumental Activities of Daily Living Questionnaire (A-IADL-Q-SV) score

    The A-IADL-Q is a questionnaire designed to assess impairments in instrumental activities of daily living (IADL) in patients with dementia. The A-IADL-Q-SV is a short version of the A-IADL-Q, consisting of 30 items that assess instrumental daily functioning sensitive to cognitive decline. Each item is rated on a 5-point Likert scale, with higher scores indicating better functional ability.

    Time frame: Screening (-8 Week~), Week 12, Week 24

Secondary outcomes

  1. Percentage change from Baseline in plasma and Cerebrospinal Fluid(CSF) biomarkers

    Changes in plasma and CSF levels of MAO-B (Monoamine Oxidase B) specific activity, GFAP (Glial Fibrillary Acidic Protein), P-tau181 (Phosphorylated-Tau 181), P-tau217 (Phosphorylated-Tau 217), Aβ-40 (Amyloid beta 40), Aβ-42 (Amyloid beta 42), NfL (Neurofilament Light Chain), BDNF (Brain-derived Neurotrophic Factor), IL-1β (Interleukin-1β), and TNF-α (Tumor Necrosis Factor-α).

    Time frame: Screening (-8 Week~), Week 12, Week 24

  2. Percentage change from Baseline in plasma Monoamine Oxidase B (MAO-B) specific activity

    Plasma MAO-B specific activity at Week 26 compared to baseline.

    Time frame: Screening (-8 Week~), Week 26

Other outcomes

  1. Number of subjects with treatment-related Adverse Events (AEs)

    AEs will be coded using MedDRA and assessed for severity and causality using CTCAE v5.0. The number of subjects affected and the incidence rates will be presented for each treatment group.

    Time frame: Through study completion (approx. 26 weeks)

  2. Change from baseline in systolic and diastolic blood pressure

    Blood pressure will be measured in mmHg at each visit.

    Time frame: Screening (-8 Week~), Baseline (Week 0), Week 4, Week 8, Week 12, Week 24, Week 26

  3. Change from baseline in pulse rate

    Pulse rate will be measured in beats per minute.

    Time frame: Screening (-8 Week~), Baseline (Week 0), Week 4, Week 8, Week 12, Week 24, Week 26

  4. Change from baseline in body temperature

    Body temperature will be measured using a standard thermometer.

    Time frame: Screening (-8 Week~), Baseline (Week 0), Week 4, Week 8, Week 12, Week 24, Week 26

  5. Change from baseline in laboratory test results

    Laboratory parameters, including routine hematology, blood chemistry, coagulation, urinalysis, and others, will be measured. Change from baseline will be analyzed.

    Time frame: Screening (-8 Week~), Baseline (Week 0), Week 4, Week 8, Week 12, Week 24, Week 26

  6. Change from baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) total score

    C-SSRS is used to assess the risk of suicide through interviews with the subject. The scores of each question are summed to range from 0 to 25 points. If "yes" from questions 4 or 5, categorize a subject as high-risk, requiring further evaluation, while other scores indicate a lower risk.

    Time frame: Screening (-8 Week~), Week 24

  7. Pharmacokinetic Parameters: Area Under the Plasma Concentration-Time Curve over the dosing interval (τ) (AUCtau) at steady-state

    AUCtau is the area under the plasma concentration-time curve over the dosing interval (τ) at steady-state, and it reflects the extent of drug exposure within a dosing cycle.

    Time frame: Baseline (Week 0), Week 12

  8. Pharmacokinetic Parameters: Peak Plasma Concentration at Steady State (Cmax,ss)

    The highest plasma drug concentration observed during a dosing interval at steady state.

    Time frame: Baseline (Week 0), Week 12

  9. Pharmacokinetic Parameters: Minimum Plasma Concentration at Steady State (Cmin,ss)

    The lowest plasma drug concentration during a dosing interval at steady state, usually occurring right before the next dose.

    Time frame: Baseline (Week 0), Week 12

  10. Pharmacokinetic Parameters: Average Plasma Concentration at Steady State (Cav,ss)

    The average plasma concentration over the dosing interval at steady state. Calculated as: Cav, ss = AUCtau/τ

    Time frame: Baseline (Week 0), Week 12

  11. Pharmacokinetic Parameters: Time to Maximum Plasma Concentration at Steady State (Tmax,ss)

    The time taken to reach the maximum plasma concentration after dosing at steady state.

    Time frame: Baseline (Week 0), Week 12

  12. Pharmacokinetic Parameters: Terminal Elimination Half-life (t1/2)

    The time required for the plasma concentration of the drug to decrease by half.

    Time frame: Baseline (Week 0), Week 12

  13. Pharmacokinetic Parameters: Peak-Trough Fluctuation at Steady State (PTF)

    A measure of the fluctuation between the peak (Cmax,ss) and trough (Cmin,ss) plasma concentrations during a dosing interval.

    Time frame: Baseline (Week 0), Week 12

07

Study locations

8 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jun 2027, 22 months after the start.

Of 42 industry-sponsored phase 2 interventional studies under Cognitive Dysfunction, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 39. This study's planned 22 months is close to that.

Counting every sponsor, half of 187 studies reached it within 42 months; a quarter within 22 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2025
First posted
Jun 18, 2025
StartActual
Aug 6, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07027072
Lead sponsor
NeuroBiogen Co., Ltd
Responsible party
Sponsor
First posted
Jun 18, 2025
Start date
Aug 6, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jun 22, 2026

Study contacts

Yeonsil Moon, Professor
Contact
neuro_reply@neurobiogen.com
+82)70-4018-8009
Dayoung Kim, Professor
Contact
Sangwook Kim, Chief Executive Officer
study director · NeuroBiogen Co., Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion